Jan 6, 2022 · Dosage Form: Sterile aqueous suspension
Depo-Provera CI (medroxyprogesterone acetate sterile aqueous suspension 150 mg/mL) 1 mL vial: 150 mg/mL: NDC 0009-0746-30: 25 × 1 mL vials: 150 mg/mL: NDC 0009-0746-35 : Depo-Provera CI prefilled syringes packaged with 22 gauge × 1 1/2 inch Terumo® SurGuard™ Needles: 1 mL prefilled syringe: 150 mg/mL: NDC 0009-7376-11 Depo-Provera® CI Medroxyprogesterone Acetate 150 mg / mL Injection Single-Dose Vial 1 mL Pfizer 00009074630 150 mg / mL: Type: Intramuscular: UNSPSC Code: 51351612: The recommended dose is 150 mg of medroxyprogesterone acetate injectable suspension every 3 months (13 weeks) administered by deep, intramuscular (IM) injection in the gluteal or deltoid muscle
Nausea, bloating, headache, changes in appetite, weight gain, tiredness, swelling, acne, hot flashes, breast tenderness, or irritation/pain at the injection site may occur
DEPO-PROVERA Sterile Aqueous Suspension contains medroxyprogesterone acetate, which is a derivative of progesterone and is active by the parenteral and oral routes of
21, 2020 — A new study finds that the drug tocilizumab (Actemra) does not reduce the need for breathing assistance with mechanical ventilation or prevent death in
The recommended dose is 150 mg of Depo-Provera CI every 3 months (13 weeks) administered by deep, intramuscular (IM) injection in the gluteal or deltoid muscle
4
Depo-Provera CI (medroxyprogesterone acetate sterile aqueous suspension 150 mg/mL) 1 mL vial: 150 mg/mL: NDC 0009-0746-30: 25 × 1 mL vials: 150 mg/mL: NDC 0009-0746-35 : Depo-Provera CI prefilled syringes packaged with 22 gauge × 1 1/2 inch Terumo® SurGuard™ Needles: 1 mL prefilled syringe: 150 mg/mL: NDC 0009-7376-11 More common side effects
If these Medroxyprogesterone Acetate Injectable Suspension, USP for intramuscular (IM) injection is available in vials and prefilled syringes, each containing 1 mL of Medroxyprogesterone Acetate sterile aqueous suspension 150 mg/mL
The recommended dose is 150 mg of medroxyprogesterone acetate injectable suspension every 3 months (13 weeks) administered by deep, intramuscular (IM) injection in the gluteal or deltoid muscle
QUALITATIVE AND QUANTITATIVE COMPOSITION
(2
The product's dosage form is injection, suspension and is administered via intramuscular form
Features
The NDC code 67457-887 is assigned by the FDA to the product Medroxyprogesterone Acetate which is a human prescription drug product labeled by Mylan Institutional Llc
Following a single 150 mg IM dose of medroxyprogesterone acetate in eight women between the ages of 28 and 36 years old, medroxyprogesterone acetate concentrations, measured by an extracted radioimmunoassay procedure, increase for approximately 3 weeks to reach peak plasma concentrations of 1 to 7 ng/mL
Depo-Provera CI (medroxyprogesterone acetate sterile aqueous suspension 150 mg/mL) 1 mL vial: 150 mg/mL: NDC 0009-0746-30: 25 x 1 mL vials: the apparent half-life for medroxyprogesterone acetate following IM administration of Depo-Provera CI is approximately 50 days
I will post links to mcare/caid website and the article that covers this change as well as the FDA page showing the